Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOV03 in Dry Eye Disease (SEECASE)
NCT03333057Phase 2Completed
- Sponsor
- Novaliq GmbH
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of perfluorohexyloctane in dry eye disease (DED) (4 arms), sponsored by Novaliq GmbH. Primary endpoint: Total Corneal Fluorescein Staining at 8 weeks. Started Jan 2018; status: completed.
02
Drugs
perfluorohexyloctane
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03333057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333057.